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Abstract
Background: Although the addition of bevacizumab significantly improves the efficacy of chemotherapy for
advanced breast cancer, regulatory concerns still exist with regard to the magnitude of the benefits and the overall
safety profile.
Methods: A literature-based meta-analysis to quantify the magnitude of benefit and safety of adding bevacizumab
to chemotherapy for advanced breast cancer patients was conducted. Meta-regression and sensitivity analyses
were also performed to identify additional predictors of outcome and to assess the influence of trial design.
Results: Five trials (3,841 patients) were gathered. A significant interaction according to treatment line was found
for progression-free survival (PFS, p = 0.027); PFS was significantly improved for 1
st line (Hazard Ratio, HR 0.68, p <
0.0001), with a 1-yr absolute difference (AD) of 8.4% (number needed to treat, NNT 12). A non-significant trend was
found in overall survival (OS), and in PFS for 2
nd line. Responses were improved with the addition of bevacizumab,
without interaction between 1
st line (Relative Risk, RR 1.46, p < 0.0001) and 2
nd line (RR 1.58, p = 0.05). The most
important toxicity was hypertension, accounting for a significant AD of 4.5% against bevacizumab (number needed
to harm, NNH 22). Other significant, although less clinically meaningful, adverse events were proteinuria,
neurotoxicity, febrile neutropenia, and bleeding. At the meta-regression analysis for 1
st-line, more than 3 metastatic
sites (p = 0.032), no adjuvant chemotherapy (p = 0.00013), negative hormonal receptor status (p = 0.009), and prior
anthracyclines-exposure (p = 0.019), did significantly affect PFS.
Conclusions: Although with heterogeneity, the addition of bevacizumab to 1
st-line chemotherapy significantly
improves PFS, and overall activity. Hypertension should be weighted with the overall benefit on the individual basis.
Introduction
Breast cancer is the cancer with the highest incidence in
women, and the major cause of death worldwide [1,2].
About 6% of patients with breast cancer present with
advanced disease ab initio, while 40% of patients with loca-
lized disease subsequently develop distant metastases [2].
Despite numerous advances in early diagnosis and
treatment in local and systemic, metastatic breast cancer
remains an incurable disease and the main objective of
therapy is both the prolongation of survival and the
improvement of associated symptoms (palliative intent),
with particular reference to delay the onset of symptoms,
improvement in progression-free survival (dominant clin-
ical endpoint used to support marketing authorizations in
this setting), and improvement of quality of life [3].
Metastatic breast cancer is a heterogeneous disease
whose evolution is difficult to predict. Choosing the best
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aspects of patient characteristics, the disease characteris-
tics and possible adjuvant treatment received (cumula-
tive dose of anthracyclines, long-term toxic effects,
possible administration of taxanes and/or trastuzumab)
[4]. As a future perspective, the combination of clinical
and molecular factors will guide the clinician in identify-
ing the most effective therapy for a given patient, leaving
more space and giving more importance to the molecu-
lar characteristics of cancer [5,6].
Angiogenesis represents an important step in the
pathogenesis, invasion, progression and development of
metastatic phenotype of breast cancer and is regulated by
pro-angiogenic factors such as vascular endothelial
growth factor (VEGF)[7]. High expression levels of VEGF
are associated with a poor prognosis and reduced survival
in patients with breast cancer [8,9]. In this context, the
theoretical block of tumor neo-vascularization be realized
by monoclonal antibodies to factor soluble serum VEGF
to its receptor or VEGFR (in different isoforms) or small
molecules directed to the tyrosine-kinase receptor that
appears to be a valid rationale for setting effective thera-
pies [10]. Bevacizumab is a humanized anti-VEGF anti-
body approved in combination with paclitaxel for first
line treatment of advanced HER2-negative breast cancer.
Although bevacizumab showed modest benefits as sin-
gle agent, numerous preclinical studies have demon-
strated synergy between anti-angiogenic therapy and
chemotherapy [12]. The addition of Bevacizumab to
chemotherapy in patients with HER-2 negative breast
cancer is now one of the most viable treatment options,
as the combination studies so far presented and pub-
lished show that this association is able to increase the
PFS and objective response [13-16].
In order to explore the magnitude of the benefit of add-
ing Bevacizumab to chemotherapy for metastatic breast
cancer with particular attention to safety, we conducted a
meta-analysis.
Methods
The analysis was conducted following 4 steps: definition
of the outcomes (definition of the question the analysis
was designed to answer), definition of the trial selection
criteria, definition of the search strategy, and a detailed
description of the statistical methods used [17,18].
Outcome definition
The combination of chemotherapy and Bevacizumab
(Beva) was considered as the experimental arm and che-
motherapy as the standard comparator. Analysis was
conducted in order to find significant differences in pri-
mary and secondary outcomes. Primary outcomes for the
magnitude of the benefit analysis were both the Progres-
sion Free Survival (PFS: time between randomization and
progression or death from any cause) and the overall sur-
vival (OS: time between randomization and death for any
cause). Secondary end-points were: overall response rate
(ORR), and grade 3-4 toxicities.
Search strategy
Deadline for trial publication and/or presentation was
June 30
th, 2010. Updates of Randomized Clinical Trials
(RCTs) were gathered through Medline (PubMed:
http://www.ncbi.nlm.nih.gov/PubMed), ASCO (Ameri-
can Society of Clinical Oncology, http://www.asco.org),
ESMO (European Society for Medical Oncology, http://
www.esmo.org), FECS (Federation of European Cancer
Societies, http://www.fecs.be), and SABCS (San Antonio
Breast Cancer Symposium, http://www.sabcs.org) web-
site searches. Key-words used for searching were:
advanced/metastatic breast cancer; chemotherapy; Beva-
cizumab; randomized; randomized; meta-analysis; meta-
regression; pooled analysis; phase III; comprehensive
review, systematic review. In addition to computer
browsing, review and original papers were also scanned
in the reference section to look for missing trials.
Furthermore, lectures at major meetings (ASCO, ESMO,
ECCO, and SABCS) having ‘advanced or metastatic
breast cancer’ as the topic were checked. No language
restrictions were applied.
Trial identification criteria
All prospective phase III RCTs published in peer-
reviewed journals or presented at the ASCO, ECCO,
ESMO and ASTRO meetings until June 2010, in which
patients with advanced or metastatic breast cancer were
prospectively randomized to chemotherapy with or
without Bevacizumab were gathered, regardless of treat-
ment lines.
Data extraction
Hazard Ratios (HR) for PFS and OS and the number of
events for secondary end-points were extracted; the last
trial’s available update was considered as the original
source. All data were reviewed and separately computed
by four investigators (F.Cu., E.B., I.S., and D.G.).
Data synthesis
HRs were extracted from each single trial for primary end-
points [19,20], and the log of relative risk ratio (RR) was
estimated for secondary endpoints [21]; 95% Confidence
Intervals (CI) were derived [22]. A random-effect model
according to DerSimonian-Laird method was preferred to
the fixed, given the known clinical heterogeneity of trials;
a Q-statistic heterogeneity test was used. Absolute benefits
for each outcome were calculated (i.e. absolute benefit =
exp {HR or RR × log[control survival]} - control survival
[23]; modified by Parmar and Machin [24]). The number
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city) for one single beneficial patient was determined
(NNT or NNH: 1/[(Absolute Benefit)/100]) [25]. Results
were depicted in all figures as conventional meta-analysis
forest plots. In order to find possible correlations between
outcome effect and negative prognostic factors (selected
among trials’ reported factors: > 3 sites, no adjuvant CT,
visceral site, hormonal receptors negative (RN), prior tax-
anes, T or anthracyclines, A) a meta-regression approach
was adopted (i.e. regression of the selected predictor on
the Log HR/RR of the corresponding outcome). Calcula-
tions were accomplished using the Comprehensive Meta-
Analysis Software, version v. 2.0 (CMA, Biostat, Engle-
wood, NJ, USA).
Results
Selected trials
Five trials (3,841 patients) were identified (Figure 1)
[13,14,16,26,27], all included in the meta-analysis, and
evaluable for PFS (primary outcome). The patients’ sam-
ple for each trial ranged from 462 to 736 patients (Table
1). One trial was conducted with a double comparison
[16]. Trials characteristics are listed in Table 1; 2 RCTs
evaluated the addition of Bevacizumab as second line
treatment [26,27], and one of these included patients
who received 2 or more regimens of chemotherapy for
metastatic disease [27]. One trial (462 patients) did not
report survival data [27], so 4 RCTs were evaluable for
OS (3,379 patients). With regard to secondary outcomes,
all RCTs were evaluable for ORR, HTN, Bleeding, Pro-
teinuria and Thrombosis; 4 RCTs (3,379 patients) were
evaluable for Neurotoxicity, Febrile Neutropenia, Gas-
tro-intestinal perforation [13,14,16,26]. With regard to
the meta-regression analysis, 2 trials did not report data
of two previous adjuvant chemotherapy [27], 1 trial did
not refer to overall visceral disease rate [14], 1 to nega-
tive hormonal receptors [27], and 1 did not report data
for previous treatment either with taxanes and anthracy-
clines [26].
Combined Analysis
With regard to the primary outcomes, the addition of
Bevacizumab to chemotherapy increased PFS in patients
untreated for advanced disease (HR 0.68, 95% CI 0.56,
0.81, p = 0.0001), with an absolute benefit of 8.4%, cor-
responding to 12 patients to be treated for one to bene-
fit, although with significant heterogeneity (p = 0.0001)
(Table 2) (Figure 2) . A significant interaction according
to treatment lines for PFS was found (p = 0.027), given
the non significant difference between the 2 arms in sec-
ond line setting (HR 0.86, 95% CI 0.69, 1.07, p = 0.19).
No significant differences were found in OS in favor of
5 RCTs included in the 
meta-analysis (3,841 pts)
5 RCTs evaluable for PFS
(3,841 pts)
Primary Outcomes Secondary Outcomes
4 RCTs evaluable for OS
(3,379 pts)
Data not available for 
1 RCT (462pts)
4 RCTs evaluable for Neuro, FN, GI Perforation
(3,379 pts)
Data not available for 
1 RCT (462 pts)
5 RCTs evaluable for ORR, HTN, 
Bleeding, Proteinuria, Thrombosis (3,841 pts)
Figure 1 Outline of the search - Flow diagram. RCTs: randomized clinical trials; pts: patients; PFS: progression free survival; OS: overall survival;
ORR: overall response rate; HTN: hypertension; neuro: neurotixicity; FN: febrile neutropenia; GI: gastro-intestinal.
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Authors Pts Prior chemotherapy
lines for metastatic
disease
Arms > 3
sites
No
adjuvant
Chemo
Visceral
site
Hormonal
Receptors
Negative (RN)
Prior
taxanes
(T)
Prior
Anthra
(A)
Miller et
al
462 Mostly 1-2 Cap (2,500 mg/m
2/day, days 1-14)
Cap (2,500 mg/m
2/day, days 1-14) +
Beva (15 mg/kg)
49.7% NR 78.7% NR 100% 100%
Gray et
al
722 0 wPac (90 mg/m
2 day 1, 8 and 15)
wPac (90 mg/m
2 day 1, 8 and 15)+
Beva (10 mg/kg)
45.7% 34.2% 62.2% 36.7% 14.9% 37.2%
Miles et
al
736 0 Doc (100 mg/m
2)
Doc (100 mg/m
2)+ Beva 7.5 (7.5 mg/
kg)
Doc (100 mg/m
2)+ Beva 15 (15 mg/
kg)
35.0%
33.4%
54.8%
54.9%
NR 17.1%
17.1%
14.9%
16.2%
53.7%
53.5%
Dieras et
al
622
615
0 A/T
A/T + Beva (15 mg/kg)
Cap (2,000 mg/m
2/day, days 1-14)
Cap (2,000 mg/m
2/day, days 1-14) +
Beva (15 mg/kg)
54.5%
27.8%
45.2%
43.9%
70.4%
68.8%
24.0%
23.6%
15.0%
39.5%
29.9%
62.9%
Bruwski
et al
684 1 Chemo
Chemo + Beva
45.3% NR 73.1% 27.7% NR NR
Pt: patients; RN: receptor negative; T: taxanes (3-weekly Docetaxel or protein-bound paclitaxel); Anthra (A): anthracyclines (various regimens: AC, EC, FAC, FEC);
Cap: capecitabine; Beva: Bevacizumab; NR: not reported; wPac: weekly paclitaxel; Doc: docetaxel; Chemo: various chemotherapies.
Group by
Treatment Line Study name Outcome Hazard ratio and 95% CI
First Gray JCO 2009 PFS
First Dieras [A/T] ECCO 2009 PFS
First Dieras [Cap] ECCO 2009 PFS
First Miles [Beva15] JCO 2010 PFS
First Miles [Beva7.5] JCO 2010 PFS
First
Second Bruwsky SABCS 2009 PFS
Second Miller JCO 2005 PFS
Second
First Dieras [Cap] ECCO 2009 OS
First Gray JCO 2009 OS
First Dieras [A/T] ECCO 2009 OS
First Miles [Beva15] JCO 2010 OS
First Miles [Beva7.5] JCO 2010 OS
First
Second Bruwsky SABCS 2009 OS
Second
0.5 1 2
Favours BEVA Favours Control
Figure 2 Combined Results - Efficacy Outcomes (PFS, OS). CI: confidence intervals; A: anthracyclines; T: taxanes; Cap: capecitabine; Beva:
bevacizumab; PFS: progression free survival; OS: overall survival.
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tion test p = 0.69) (Table 2). Overall response were sig-
nificantly higher in the Bevacizumab arm, regardless of
treatment lines (interaction test p = 0.48), with an abso-
lute difference of 11.5% and 8.4% for first and second
line, respectively, corresponding to 8-9 and 12 patients
to be treated for one to benefit (Table 2). Significant
adverse events for patients receiving Bevacizumab are
listed in table 3. The highest significant difference
against the administration of Bevacizumab was HTN,
corresponding to 22 patients to be treated for one
experiencing the adverse events, although with signifi-
cant heterogeneity (p = 0.0001). According to the per-
formed meta-regression analysis, more than 3 involved
sites, absence of adjuvant chemotherapy, negative hor-
monal receptor status and prior administration of
anthracyclines are significant predictors of PFS benefit
(Table 4). As shown in single trials as well [14,15], prior
exposure to taxanes did not compromise the efficacy of
Bevacizumab.
Discussion
The addition of Bevacizumab to chemotherapy is con-
sidered one of the most viable treatment options in
patients with HER-2 negative metastatic breast cancer,
as distinct randomized studies so far presented and pub-
lished consistently showed that this association resulted
in significantly improved overall response rate and PFS.
Notably, the therapeutic benefit was observed in all
subgroup examined. Nevertheless, the issue of adding
B e v a c i z u m a bt o1
st line chemotherapy for advanced
breast cancer is still open, given the recent concerns
pointed out by the US Food and Drug administration
(FDA), with specific regards to the lack of significant
benefit in OS, and the toxicity profile. Moreover, the
regulatory panel withheld the indication for breast can-
cer, and the final decision is still pending. The main
question raised up by the regulatory committee refers to
the eventual amount of benefit related to the addition of
Bevacizumab. For this reason, a cumulative analysis spe-
cifically designed to weight that became mandatory.
T h ed a t ap r e s e n t e dh e r e i ns h ow a statistically signifi-
cant advantage in terms of either progression-free and
responses, with an overall absolute benefit of 8% (Table
2). The relative risk reduction in favor of the addition of
1
st line Bevacizumab is 32%, and 12 patients are needed
to treat in order to see one patient who significantly
benefit. This amount of benefit well compares with the
benefits of other important therapeutic choices such as
the addition of taxanes for the 1
st line treatment of
metastatic breast cancer, where the advantage in terms
of relative risk is about 10%.
From a global perspective, the hazard ratios for PFS
obtained in the current analysis compare well with
those obtained in other studies that have investigated
the addition of another drug in the taxane-based che-
motherapy. In the study of Albain et al [28], the addi-
tion of gemcitabine to paclitaxel for advanced breast
Table 3 Significant Toxicities results
Toxicity Pts (RCTs) RR (95% CI) p-value Het. (p) AD (%) NNH
Hypertension 3,841 (5) 5.15 (1.60, 16.6) 0.006 < 0.0001 4.5 22
Proteinuria 3,841 (5) 9.55 (3.44, 26.5) < 0.0001 0.96 0.4 250
Neurotoxicity 3,379 (4) 1.20 (1.01, 1.43) 0.044 0.61 2.6 39
Febrile Neutropenia 3,379 (4) 1.39 (1.07, 1.83) 0.015 0.60 2.1 46
Bleeding 3,841 (5) 3.05 (1.13, 8.23) 0.028 0.56 0.6 175
Pts: patients; RCTs: randomized clinical trials; HR: hazard ratio; CI: confidence intervals; Het.: heterogeneity; p: p-value; AD: absolute difference; NNH: number
needed to harm.
Table 2 Combined efficacy and activity results
Outcomes Pts (RCTs) HR/RR (95% CI) p-value Het. (p) AD (%) NNT
PFS
1
st line 2,695 (3) 0.68 (0.56, 0.81) 0.0001 0.0001 8.4 12
2
nd line 1,146 (2) 0.86 (0.69, 1.07) 0.19 0.14 --
OS
1
st line 2,695 (3) 0.95 (0.85, 1.05) 0.338 0.64 --
2
nd line 684 (1) 0.90 (0.71, 1.14) 0.38 1.00 --
ORR
1
st-line 2,695 (3) 1.46 (1.21, 1.77) < 0.0001 0.008 11.5 8-9
2
nd-line 1,146 (2) 1.58 (1.00, 2.52) 0.05 0.092 8.4 12
Pts: patients; RCTs: randomized clinical trials; HR: hazard ratio; RR: relative risk; CI: confidence intervals; Het.: heterogeneity; p: p-value; AD: absolute difference;
NNT: number needed to treat.
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apy, the HR in terms fir the time to progression is 0.70
[28]. In the phase III trial evaluating the addition of
capecitabine to docetaxel in the same setting of patients,
the HR for time to disease progression is 0.65 [29].
Taking into account the different approaches to treat-
ment such as chemotherapy combination versus single
agent therapy for first line treatment of metastatic
patients with breast cancer, the HR for taxanes based
combinations compared with control arm was 0.92 for
PFS [30]. Also with regard to the events of severe toxici-
ties that are observed in studies that explore the benefits
determined by the polychemotherapy compared to sin-
gle drug therapy, are well comparable with the increase
in hypertension that occurs in patients treated with
bevacizumab.
With regard to the concerns regarding the interpreta-
tion of those trials providing a significant (sometimes
small) benefit in intermediate end-points (such as PFS)
without any advantage in late-outcomes (such as OS), a
recent original work has been published, trying to weight
the impact of the post-progression survival (SPP, as the
difference between OS and PFS) [31]. To this purpose,
simulation methods have been used to generate clinical
2-arms studies with a median PFS of 6 and 9 months,
respectively. The authors indicated that OS represents a
reasonable primary endpoint when the SPP is short,
while when the SPP is long, that dilutes the variability of
the OS, which may consequently loose the eventual sta-
tistical significance. This particular effect is especially
true for those diseases where the SPP is longer than 1
year. In a context of effective treatments, such as
advanced breast cancer, when a clinical trial shows a sig-
nificant PFS benefit, the absence of a statistically advan-
tage for OS does not necessarily imply the absence of a
late-survival improvement [31].
Two meta-analysis analyzed the effect of the addition
of Bevacizumab to chemotherapy in metastatic breast
cancer [32,33] in over 3,000 patients in three rando-
mized trials. showing a statistically significant increase
in PFS, resulting in a reduced risk of progression of
about 30%. In the meta-analysis conducted by Valachis
et al, improved PFS was statistically significant only in
the subgroup of patients receiving taxanes (or anthracy-
clines in a part of the study RIBBON-1) in combination
with Bevacizumab [33], this advantage not seem to get
in combination with capecitabine, although the latter
are grouped in heterogeneous populations with regard
to the treatment line. In the meta-analysis conducted by
Lee et al, with populations more correctly grouped by
line of treatment rather than medication, the benefit of
the addition of Bevacizumab in PFS is restricted to first-
line treatment [32]. Moreover, this analysis shows a
marginal but statistically significant benefit in overall
survival in first line.
At the last ESMO meeting, a meta-analysis of 530
elderly patients (older than 65 years) enrolled in the
randomized trials ECOG 2100, AVADO and RIBBON-1,
was presented [34]. Although that represent a subgroup
analysis, even in these featured advanced breast cancer
patients’ sample, bevacizumab in combination with che-
motherapy was associated with significantly improved
PFS versus chemotherapy alone (HR 0.67, p = 0.0030).
Hypertension was more frequent with the addition of
bevacizumab, as expected; besides, no differences
according to age were found.
Another relevant issue that emerges from our analysis is
that the prior exposure to treatments containing taxanes
does not affect the efficacy of bevacizumab (Table 4).
Indeed, the meta-regression analysis for either PFS or OS
clearly indicates that no significant correlation exists
between the efficacy of bevacizumab and taxanes pre-
treatment (p = 0.96 and p = 0.45, respectively). This find-
ing is consistent with the ECOG-2100 and AVADO pre-
vious release [14,15], and with the recently presented
meta-analysis of patients from studies ECOG-2100,
AVADO and RIBBON-1, previously treated with taxanes
(paclitaxel, docetaxel or paclitaxel protein-bound) [35].
This analysis included only 311 patients from the group of
patients treated with taxanes of the RIBBON-1 and
AVADO who received bevacizumab 15 mg/kg. The addi-
tion of bevacizumab led to an improvement in PFS from
6.2 to 10.6 months (HR 0.50, 95% CI 0.36-0.69). In line
with the data of the single trials and our analysis, the
authors conclude that patients pretreated with taxanes are
good candidates for retreatment with bevacizumab and
taxane [35].
With regard to serious adverse events, the main signif-
icant toxicity against the addition of bevacizumab was
hypertension (Table 3); this represents a common find-
ing in all disease setting when this monoclonal antibody
is adopted. Our analysis shows that a weighted average
Table 4 Meta-regression Analysis
Outcome Predictor p-value
> 3 sites No adjuvant Chemo Visceral site Hormonal Receptors Negative Prior taxanes Prior Anthra
PFS 0.032 0.00013 0.03 0.009 0.96 0.019
OS 0.99 0.18 0.56 0.66 0.45 0.91
Anthra (A): anthracyclines PFS: progression free survival; OS: overall survival.
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undergoing bevacizumab was found, corresponding to
22 patients to be treated for one harmed (Table 3).
These data are in line with those recently reported in
two further cumulative analyses on the individual
patients’ basis, where hypertension seems to occur with
different rates according to the chemotherapeutic beva-
cizumab is combined with [34,35]. Indeed, the initial 14-
17% rate reported in the ECOG-2100 trial should be
carefully evaluated, given the adoption of paclitaxel on a
weekly basis (with its steroid pre-medication) could
have biased the specific toxicity rate. The other signifi-
cant toxicities seem to occur rarely, and in particular
those toxicities supposed to be bevacizumab-related (i.e.
proteinuria, bleeding) require 175-250 patients to be
treated for one to be harmed. From a very practical per-
spective, in order to weight the relative severities of
positive and negative events, breast cancer patients
receiving bevacizumab in addition to chemotherapy
have ‘likelihood to be helped and harmed’ (LHH) of 2-
20 [36]; that means that patients receiving bevacizumab
a r ef r o m2t o2 0t i m e sm o r el i k e l yt ob eh e l p e dt h a n
armed.
Recently, other anti-angiogenesis drugs have been stu-
died in randomized trials for locally advanced or meta-
static breast cancer [37-39]. In the SOLTI-0701 study,
patients randomized to the combination of sorafenib and
capecitabine showed a median PFS of 6.4 months, com-
pared to the 4.1 months achieved by the patients who
received capecitabine alone (HR 0.58, p = 0.0006) [38],
although with a higher incidence of serious adverse events
(hand-foot syndrome 45% versus 13%). A further rando-
mized phase II study evaluated the efficacy and toxicity of
sorafenib in addition to paclitaxel compared to paclitaxel
plus placebo in patients untreated for metastatic disease,
demonstrating a statistically significant improvement in
PFS, TTP and responses [39]. Also for the first line treat-
ment, the first analysis of a 3-arm randomized trial com-
paring paclitaxel plus placebo or bevacizumab or
motesanib (small molecule inhibitor of VEGF tyrosine
kinase) has been recently presented, with a median follow
up of 10 months [40]. No significant differences in the pri-
mary objective of the study (the response rate), were
found between the three arms, at the expense of a higher
grade 3 and 4 incidence of neutropenia, hepato-biliary and
gastrointestinal toxicity for patients receiving motesanib.
For the second line setting of HER-2 negative patients, a
recent trial randomizing patients between capecitabine
and sunitinib, did not show any PFS superiority of the tyr-
osine kinase over capecitabine [37].
More concerning data with regard to the overall safety
profile of bevacizumab have been recently released
[41,42]: in the context of a literature based meta-analysis
evaluating the addition of bevacizumab to chemotherapy
or biologics accruing data of more than 10,000 patients
regardless of the cancer type, the rate of treatment-
related mortality was significantly higher in the experi-
mental arm [41,43]. Deaths seem to be associated with
hemorrhage, neutropenia and gastrointestinal perfora-
tion, with a significant interaction according to the che-
motherapeutics combined (against the use of platinum
or taxanes). With specific regard to breast cancer, a
further meta-analysis recently showed a statistically sig-
nificant higher risk of heart failure with bevacizumab
[41]; both meta-analyses report no interaction according
to the bevacizumab dose as a common finding.
Although all these data require an individual patient
data analysis for the competitive death risk evaluation,
in order to clearly correlate the adverse events together,
and even taking into account the heterogeneity across
all studies and settings, many concerns still remain for
the wide adoption of this agents [43,44].
Conclusions
Our data in context with the other exploring the safety-
efficacy balance of the addition of bevacizumab to che-
motherapy for advanced breast cancer do strengthen the
need of a deep analysis of the correlation between
adverse events and deaths on one side, and the maximi-
zation of the efficacy by restricting the drug to those
patients who will really benefit. The latest approach is
far to be understood, although positive hints with regard
to polymorphisms analyses are encouraging. Bevacizu-
mab, from a clinical practice standpoint, slightly
increases the efficacy of chemotherapy in HER-2 nega-
tive advanced breast cancer, although a close follow-up
monitoring for adverse events must be adopted.
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